European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.
There seems to be a relationship between a patient’s willingness to switch to a biosimilar and health literacy, according to study presented by Milada Cvancarova Smastuen and colleagues at the European League Against Rheumatism’s Annual European Congress of Rheumatology in June in Amsterdam. About one in five patients taking etanercept (Enbrel) or infliximab (Remicade) who were switched to less expensive biosimilars said that they were dissatisfied. But the study adds that the patients’ level of satisfaction with the switch was associated with health literacy, which researchers defined as being given sufficient and necessary information about their health.
Source: Center for Biosimilars